EHA 2023 | Post hoc analysis comparing the safety profile of zanubrutinib vs ibrutinib in B-cell malignancies
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the results of a post hoc analysis of a large clinical trial database comparing the safety profiles of zanubrutinib and ibrutinib in patients with B-cell malignancies. It was shown that zanubrutinib was associated with a lower rate of serious adverse events, cardiac events, and treatment discontinuation. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Zanubrutinib is a second generation covalent BTK inhibitor, and it was compared head-to-head with ibrutinib in the APLINE study. In the APLINE study, we found that there were lower rates of serious adverse events, lower rates of drug holds, drug discontinuation with zanubrutinib compared to ibrutinib as well as lower rates of permanent discontinuation with zanubrutinib. The rate of infections was fairly similar, and the rate of hypertension was fairly similar in ALPINE...
Zanubrutinib is a second generation covalent BTK inhibitor, and it was compared head-to-head with ibrutinib in the APLINE study. In the APLINE study, we found that there were lower rates of serious adverse events, lower rates of drug holds, drug discontinuation with zanubrutinib compared to ibrutinib as well as lower rates of permanent discontinuation with zanubrutinib. The rate of infections was fairly similar, and the rate of hypertension was fairly similar in ALPINE. Although when you look more broadly across the zanubrutinib experience, as we did for the poster here at EHA, you’ll see that hypertension is lower overall with zanubrutinib, that ALPINE is a bit of an outlier in that regard. And what we particularly saw in ALPINE, and also still see in the larger cohort, is that the risk of cardiac events is significantly lower with zanubrutinib compared to ibrutinib – fewer serious cardiac adverse events, fewer drug discontinuations and notably no cardiac deaths versus six with ibrutinib which was 2%.
Read more...
Disclosures
JRB has served as a consultant for Abbvie, Acerta/Astra-Zeneca, Alloplex Biotherapeutics, BeiGene, Genentech/Roche, Grifols Worldwide Operations, Hutchmed, iOnctura, Janssen, Kite, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, TG Therapeutics.
